VERA Trutakna: ORIGIN 3 eGFR Readout Decides Approval

The $2.46 billion question hanging over Vera Therapeutics is not whether Trutakna works. It is whether the confirmatory eGFR data, due within weeks, shows that atacicept slows kidney function decline, the one thing that turns an accelerated approval into a durable one. Vera closed at $34.19 on August 28 with a $2.46 billion market cap and roughly $597 million in cash. The stock has already run 18% off its August 13 low of $28.89 as traders position ahead of the readout. Everything else about the company is a rounding error next to one number: the placebo-adjusted eGFR slope in ORIGIN 3.

The stakes are not abstract. IgA nephropathy is the most common primary glomerulonephritis worldwide, and it is a leading cause of kidney failure. Roughly 160,000 Americans have it, and 30% to 40% of diagnosed patients progress to end-stage renal disease within two decades. The commercial market was pegged near $1.5 billion in 2025 and is growing around 18% a year as new drugs expand the treated population. That is real money, and it is the reason seven drugs across five mechanisms are now fighting over it. Vera is the highest-torque pure play in the fight, because its entire approval status is riding on a single, imminent data readout.

The approval that is not yet real. On July 7 the FDA granted Trutakna (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. It is the first and only dual BAFF/APRIL inhibitor cleared for the disease. Mechanically, it is a soluble fusion protein built on the TACI receptor that binds both BAFF and APRIL, the two cytokines that drive B cells to produce the galactose-deficient IgA1 at the root of the disease. Blocking both is the differentiator, and it is why the drug sits upstream of the kidney, attacking antibody production rather than the inflammation downstream. The approval rested on a prespecified 36-week interim analysis of ORIGIN 3: atacicept cut 24-hour urine protein-creatinine ratio 46% from baseline, a 42% reduction versus placebo (p<0.0001), in the first 203 participants. The Phase 3 data were published in the New England Journal of Medicine (Lafayette et al, NEJM 2026;394:647-657). Good, but proteinuria is a surrogate. The label says so explicitly: it has not been established that Trutakna slows kidney function decline. That is exactly what the confirmatory analysis must now show.

The trial and the endpoint. ORIGIN 3 is a global, randomized, double-blind, placebo-controlled Phase 3 that randomizes patients 1:1 to atacicept 150 mg weekly by subcutaneous autoinjector or placebo. The confirmatory endpoint is estimated glomerular filtration rate, the slope of kidney function over time, not proteinuria. That distinction is the whole trade. Proteinuria is a biomarker the FDA accepted as a surrogate for accelerated approval. eGFR slope is the hard endpoint that decides full approval. Vera originally guided the eGFR readout to 2027, then, after aligning with the FDA in June, pulled it forward to the third quarter of 2026, with a supplemental BLA planned for Q4 2026 if the data are supportive. The readout is now imminent, which is why the stock is coiled.

What the data has to show. The benchmark is Fabhalta. Novartis converted iptacopan to traditional approval on July 16 on an annualized total eGFR slope of -3.10 mL/min/1.73m² per year versus -6.12 on placebo, a 3.02-unit treatment effect and a 49.3% slower decline over 24 months. That is the bar a confirmatory readout in IgAN is measured against. Filspari set the floor at a 1.2-unit effect (p=0.0168) when it converted in 2024, and Voyxact’s VISIONARY trial posted a +5.5-unit eGFR treatment effect, the cleanest number in the field. For Trutakna to convert, Vera needs a statistically significant placebo-adjusted eGFR slope, and the closer it lands to Fabhalta’s 3.02 units, the more durable the approval. The reason to like Vera’s odds is the Phase 2b run-in: through 96 weeks atacicept produced a mean annualized eGFR slope of -0.6 mL/min/1.73m², essentially flat and consistent with a healthy kidney, alongside a 66% reduction in galactose-deficient IgA1, resolution of hematuria in 75% of patients, and a 52% reduction in proteinuria. If that flatness survives the placebo comparison in the larger ORIGIN 3, Vera has its conversion.

There is a subtlety worth understanding before the readout, because it is where sloppy takes go wrong. In ORIGIN 3 the 68% reduction in galactose-deficient IgA1, the disease-driving antibody, was reported as a secondary endpoint with observational results only, meaning it was not protected by the trial’s statistical multiplicity adjustment. That is fine as a mechanistic signal, but it is not the same as a powered endpoint. The confirmatory readout is powered on eGFR, and eGFR is the only number that matters for the label. Everything else is context.

The competitive fight, honestly. Even a conversion does not hand Vera the market. Trutakna is fighting Filspari, Tarpeyo, Fabhalta, atrasentan, and Voyxact for share in an indication the largest estimates put at only $3 billion, and every one of those drugs is layered on top of maximally tolerated RAS blockade plus, increasingly, SGLT2 inhibitors. None of them replaces the background standard of care; they are all add-ons to it. Its proteinuria effect, 42% versus placebo, is the smallest of the accelerated class. Vertex’s povetacicept, with a November 30 PDUFA, posted a 49.8% placebo-adjusted reduction and a 77.4% drop in galactose-deficient IgA1, and its every-four-week dosing beats Trutakna’s weekly schedule on convenience. Travere’s Filspari, the only drug with a head-to-head Phase 3 win, trades at $6.19 billion, more than double Vera’s cap, and is the foundational therapy the others get stacked on. The bull case for Vera is mechanism purity and a clean confirmatory number. The bear case is that it entered sixth, with the weakest proteinuria delta, and the FDA’s willingness to convert a weak-proteinuria drug depends entirely on an eGFR number nobody outside the trial has seen.

The risks and the math. The specific risk is not generic biotech risk. It is that ORIGIN 3’s eGFR treatment effect is small or its confidence interval crosses zero, which would put the accelerated approval itself in question and force a de-rate. There is also a timing risk: the readout is guided to the third quarter, and if it slips into Q4, the catalyst and the premium get dragged out with it. Safety is not the worry here; the 428-patient safety population was generally well tolerated, with infections and local administration reactions as the most common adverse reactions, the standard profile for an upstream B-cell modulator. The cushion is cash: $597 million and no debt, roughly a quarter of the market cap, enough to fund a launch even on a miss. The setup is asymmetric in the right direction for a catalyst bet. Analysts cluster at $74 to $80 on a conversion, with Wedbush the outlier at $43. If the eGFR data confirms a flat slope versus placebo, the stock re-rates toward $60 plus. If it misses, the cash argues for a floor in the low $20s, a 35% to 40% drawdown.

The verdict. Own this into the readout, but size it like the binary it is: 1% to 2% of a biotech portfolio, not a core holding. The Phase 2b slope of -0.6 is the number that matters in the IgAN trade, and Fabhalta’s conversion three weeks after Trutakna’s approval proved the FDA is now converting IgAN drugs on eGFR slope, not making them wait. That is the pattern now: Tarpeyo converted in 2023, Filspari in 2024, Fabhalta in 2026, and Vera is next in line if the data cooperates. That precedent is real and it favors Vera. The risk is the proteinuria gap: if the mechanism that drove the weakest surrogate in the class also drives a weak hard endpoint, the premium evaporates. The trade rests on the understanding that a hit doubles the stock and a miss costs a third of it.